175 related articles for article (PubMed ID: 28739756)
1. Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
Chu H; Du F; Gong Z; Lian P; Wang Z; Li P; Hu B; Chi C; Chen J
Anticancer Res; 2017 Aug; 37(8):4587-4591. PubMed ID: 28739756
[TBL] [Abstract][Full Text] [Related]
2. Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin.
Jiang L; Li P; Gong Z; Hu B; Ma J; Wang J; Chu H; Zhang L; Sun P; Chen J
Anticancer Res; 2016 Mar; 36(3):1313-8. PubMed ID: 26977031
[TBL] [Abstract][Full Text] [Related]
3. Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancement.
Xu Q; Shao J; Su S; Wei J; Chen F; Meng F; Zhao Y; Du J; Zou Z; Qian X; Liu B
Cell Immunol; 2018 Sep; 331():1-8. PubMed ID: 29903664
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of intrapleural OK-432 and cisplatin for malignant pleural effusion in lung cancer patients].
Shimizu T; Takahashi N; Terakado M; Sato M; Sugane T; Kisohara A; Akusawa H; Tsujino I; Horie T
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1139-43. PubMed ID: 16121916
[TBL] [Abstract][Full Text] [Related]
5. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
Han B; Jia Y; Zhou M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
8. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.
Zhao WY; Chen DY; Chen JH; Ji ZN
Cell Biochem Biophys; 2014 Sep; 70(1):623-8. PubMed ID: 24920191
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.
Zhan Z; Wang X; Yu J; Zheng J; Zeng Y; Sun M; Peng L; Guo Z; Chen B
Future Oncol; 2022 Mar; 18(10):1259-1271. PubMed ID: 35114805
[TBL] [Abstract][Full Text] [Related]
10. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
11. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
12. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
13. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin.
Dong M; Li X; Hong LJ; Xie R; Zhao HL; Li K; Wang HH; Shin WD; Shen HJ
J Int Med Res; 2008; 36(6):1273-8. PubMed ID: 19094436
[TBL] [Abstract][Full Text] [Related]
14. Clinical observation on the efficacy of Xiaoshui decoction combined with intrapleural perfusion of cisplatin in treating malignant pleural effusion.
SHI Z; HE QY; HUA BJ
Chin J Integr Med; 2008 Dec; 14(4):257-61. PubMed ID: 19082796
[TBL] [Abstract][Full Text] [Related]
15. [Negative pleural cytology after intrapleural perfusion hyperthermo-chemotherapy for malignant pleural effusion].
Yagi T; Ueda K; Kaneda Y; Sakano H; Tanaka T; Matsuoka T; Sudo M; Hayashi M; Hamano K
Kyobu Geka; 2004 Feb; 57(2):107-10. PubMed ID: 14978902
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer.
Ishida A; Miyazawa T; Miyazu Y; Iwamoto Y; Zaima M; Kanoh K; Sumiyoshi H; Doi M
Respirology; 2006 Jan; 11(1):90-7. PubMed ID: 16423208
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
Rusch VW; Figlin R; Godwin D; Piantadosi S
J Clin Oncol; 1991 Feb; 9(2):313-9. PubMed ID: 1988578
[TBL] [Abstract][Full Text] [Related]
18. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study.
Chen WJ; Yuan SF; Yan QY; Xiong JP; Wang SM; Zheng WE; Zhang W; Sun HY; Chen H; Wu LL
Cancer Invest; 2012 Feb; 30(2):126-30. PubMed ID: 22148972
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
Hori T; Mise K; Kan N; Okino T; Satoh K; Yamasaki S; Teramura Y; Harada T; Ohgaki K; Kodama H
Biotherapy; 1992; 5(1):21-9. PubMed ID: 1389900
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion.
Ba M; Long H; Wang Y; Tang Y; Wu Y; Zhang X; Cui S
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2005-12. PubMed ID: 24072234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]